A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.


Pharmaceutical Technology
pp. s28-s31

Acknowlegments

This work was supported in part by the National Cancer Institute of the National Institutes of Health under award number R43CA126070 and R43CA128752. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Brian Schram, PhD, is a senior scientist, Matt Howard is a research scientist, Marjorie Curet is a senior scientist, and Rachel Kravitz, PhD, is director of research, all at Neoclone, Madison WI. Voula Kodoyianni, PhD*, is a product manager at Thermo Fisher Scientific, Madison, WI. *

References

1. Datamonitor Pipeline Insight, "Biologic Targeted Cancer Therapies, Next Generation Jostles for Market Position," DMHC2573. (2009).

2. G. Kohler and C. Milstein, Nature 256, 495–497 (1975).

3. R. Fagnani, Immunol Ser 61, 3–22 (1994).

4. R. Fagnani, S. Halpern, and M. Hagan, Nucl. Med. Commun. 16, 362–369 (1995).

5. M. B. Khazaeli, R. M. Conry, and A. F. LoBuglio, J. Immunother. Emphasis Tumor Immunol. 15, 42–52 (1994).

6. P. Mitchell, Nat. Biotechnol. 23, 906 (2005).

7. M. C. Via, "Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment," (Insight Pharma Reports, 2010).

8. N. R. Gonzales et al., Mol. Immunol. 41, 863–872 (2004).

9. S. V. Kashmiri et al., Methods 36, 25–34 (2005).

10. J. Osbourn, M. Groves, and T. Vaughan, Methods 36, 61–68 (2005).

11. D. M. Fishwild et al., Nat. Biotechnol. 14, 845–851 (1996).

12. L. L. Green, J. Immunol. Methods 231, 11–23 (1999).

13. L. L. Green et al., Nat. Genet. 7, 13–21 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here